Form 4: Castle Biosciences CEO Sells Shares Under 10b5-1 Plan

Castle Biosciences' President and CEO, Derek J. Maetzold, reported the exercise of stock options and subsequent sale of common stock under a pre-arranged Rule 10b5-1 plan.

Summary

• Derek J. Maetzold, President & Chief Executive Officer and a Director of Castle Biosciences Inc. (CSTL), reported transactions on March 26, 2026.
• Maetzold exercised 550 stock options at an exercise price of $2.39 per share.
• Concurrently, Maetzold sold a total of 4,172 shares of common stock at a weighted-average sale price of $25.551 per share.
• The sales included 550 shares held directly and 3,622 shares held indirectly through various trusts.
• These transactions were executed pursuant to a Rule 10b5-1 plan adopted by Maetzold on December 3, 2025.
• Following these transactions, Maetzold directly beneficially owns 21,479 shares of common stock and indirectly owns 254,114 shares through various trusts.
• Maetzold also holds 13,732 fully vested stock options with an exercise price of $2.39 and an expiration date of November 11, 2028.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction under a pre-arranged plan, which typically has a neutral to slightly positive market sentiment as it represents an executive diversifying holdings and realizing value from options, rather than a direct vote of no confidence in future stock price appreciation.

Positives

• The exercise of stock options at a low price ($2.39) and subsequent sale at a significantly higher price ($25.551) indicates a substantial personal gain for the executive.
• The transactions were conducted under a Rule 10b5-1 plan, which demonstrates pre-planning and adherence to insider trading regulations, reducing the perception of opportunistic trading.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be interpreted by the market as a lack of confidence in the company's near-term growth prospects, although this is mitigated by the pre-planned nature.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that insider sales executed under a Rule 10b5-1 plan are a common practice for executives to manage personal financial planning, diversify their portfolios, and ensure compliance with insider trading laws by pre-scheduling transactions. Such sales are generally viewed as less indicative of management's sentiment about the company's future than unscheduled sales.

Related Party Transactions

• Sales of common stock were made indirectly through The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, and various Maetzold 2018 Remainder Trusts, where the Reporting Person or his spouse serves as trustee and/or beneficiaries are family members.

Stakeholder Impact

• Shareholders may interpret the insider selling as a routine diversification of personal assets, especially given the Rule 10b5-1 plan, rather than a negative signal about the company's prospects.

Key Dates

Recommendation

The reported transactions are routine insider sales executed under a pre-established Rule 10b5-1 plan. Such transactions typically do not signal a change in the company's fundamental outlook or warrant a shift in investment strategy based solely on this filing. Investors should consider broader company performance and market conditions.

Keywords

Castle Biosciences, CSTL, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Derek Maetzold, Rule 10b5-1